Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
Résultats de la recherche
Tout
Rechercher les filtres
-
COLUMBUS, Ohio and CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat...
-
COLUMBUS, Ohio, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
-
COLUMBUS, Ohio, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
-
COLUMBUS, Ohio, and SAN FRANCISCO, Nov. 02, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically...
-
COLUMBUS, Ohio, Nov. 02, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
-
COLUMBUS, Ohio, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
-
The findings were published Sept. 27 in the peer-reviewed journal Science AdvancesLasofoxifene was more effective than fulvestrant in inhibiting estrogen activity in mice models COLUMBUS, Ohio,...
-
COLUMBUS, Ohio and SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat...
-
COLUMBUS, Ohio, July 18, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
-
In preclinical mouse models, results suggested lasofoxifene could be an effective therapy for all hormone treatment-resistant breast tumorsPhase 3 ELAINE-3 study is currently investigating...